LINC02219

Across TCGA pan-cancer cohorts, LINC02219 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of LINC02219’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where LINC02219 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02219 is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.

LIHC, ESCA, and LUSC are the cancer types where LINC02219 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC02219 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.076	.001	5	view →
ESCA	All	II,III,IV	+0.285	<.001	2	view →
LUSC	Male	II,III,IV	−0.038	.040	2	view →
KIRC	All	All	+0.026	.019	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

LINC02219–LIHC

Open the LIHC breakdown →